TREATMENT TARGETED FOR LC-FAOD: The FDA has approved a second rare disease drug from California-based Ultragenyx in the space of a fortnight, for treatment of long-chain fatty acid oxidation disorders. Ultragenyx said the regulator approved Dojolvi (tripetanoin) as source of calories and fatty acids for children and adults with confirmed disorders. This group […]